# OUTCOMES OF CONSOLIDATIVE ALLOGENEIC TRANSPLANTATION AFTER VENETOCLAX PLUS HYPOMETHYLATING AGENT INDUCTION IN ACUTE MYELOID LEUKEMIA: A SINGLE-CENTER RETROSPECTIVE STUDY

**M. Tamutytė-Jankauskė[1,2], M. Mikalonytė[1,2], T. Smalinskaitė[1,2], G. Daukėlaitė[1,2], L. Kevličius[1], L. Davainis[1], I. Trociukas[1], A. Slobinas[1], R. Jucaitienė[1], I. Šlepikienė[1], R. Kviliūtė[1], R. Batiuškaitė[1], L. Griškevičius[1,2] and A. Žučenka[1,2]**

1. Vilnius University Hospital Santaros Klinikos, Hematology, Oncology, and Transfusion Medicine Center, Vilnius, Lithuania
2. Vilnius University, Faculty of Medicine, Institute of Clinical Medicine, Vilnius, Lithuania

Vilniaus universiteto ligoninė
SANTAROS KLINIKOS
HOTC HEMATOLOGIJOS, ONKOLOGIJOS IR TRANSFUZIOLOGIJOS CENTRAS

## INTRODUCTION

Venetoclax combined with hypomethylating agents (Ven+HMA) has emerged as the standard low-intensity induction strategy for AML patients ineligible for intensive chemotherapy[1,2]

## AIM

To present a single-center experience of allogeneic hematopoietic stem cell transplantation (allo-HSCT) following Ven+HMA induction in AML and AML with myelodysplastic changes (AML/MDS).

## METHODS

- **Single-center retrospective** study
- **24 patients** with AML (n=17) or AML/MDS (n=7), treated between 2023 – 2025
- Primary outcomes: pre- and post-transplant MRD status (flow cytometry <0.1% and/ or molecular), best response, overall survival, relapse, non-relapse mortality and GVHD

| | |
|---|---|
| **Induction regimen** | VEN7/14-DAC5 (n=16, 66.7%)<br>AZA7-VEN7/14 (n=8, 33.3%) |
| **Conditioning regimen** | myeloablative (MAC) (n=3, 12.5%)<br>reduced-intensity (RIC) (n=21, 87.5%) |
| **Donors** | matched unrelated (MUD; n=16, 66.7%)<br>haploidentical (n=6, 25%)<br>matched sibling (MSD; n=2, 8.3%). |

## CONCLUSIONS

In our cohort, allo-HSCT after Ven+HMA bridging **demonstrated favorable outcomes despite a substantial proportion of patients being MRD-positive prior to transplantation.** Transplant-related mortality and graft-versus-host disease remain the key challenges.

## RESULTS




Figure 1. Kaplan-Meier Estimates of Overall and Relapse-Free Survival. Statistical visualization (Kaplan-Meier analysis) performed using Claude (Anthropic).

| Cohort | |
|---|---|
| Patients proceeding to allo-HSCT | **24 / 135 Ven+HMA patients (17.8%)** |
| Diagnosis | **AML 17 (70.8%) · AML/MDS 7 (29.2%)** |
| Adverse risk (ELN 2022/2024) | **6 / 24 (25.0%)** |
| Median age, years (range) | **67 (36–75)** |
| Cycles of Ven+HMA before SCT, median (range) | **2 (1–4)** |
| **Pre-Transplant MRD (MFC)** | |
| MRD-negative | **9 / 24 (37.5%)** |
| MRD-positive | **15 / 24 (62.5%)** |
| **Post-Transplant Response** | |
| Complete remission (CR) | **19 / 24 (79.2%)** |
| CR with incomplete recovery (CRi) | **1 / 24 (4.2%)** |
| Morphologic leukemia-free state (MLFS) | **3 / 24 (12.5%)** |
| MRD negativity achieved | **23 / 24 (95.8%)** |
| **Outcomes at Median Follow-up (16.6 months)** | |
| Alive | **19 / 24 (79.2%)** |
| Relapse (molecular 4, morphological 3) | **7 / 24 (29.2%)** |
| Any-grade GVHD | **13 / 24 (54.2%)** |
| Death | **5 / 24 (20.8%)** |
| Median overall survival | **Not reached** |

Table 1. Baseline Characteristics, Response, and Outcomes. Statistical visualization (Kaplan-Meier analysis) performed using Claude (Anthropic).

## ACKNOWLEDGEMENTS

We thank the Department of Hematology for their support and all colleagues involved in patient care and data collection.

## CONTACT INFORMATION

milvyde.tamutyte@santa.lt

## REFERENCES

1. DiNardo, C. D., Jonas, B. A., Pullarkat, V., Thirman, M. J., Garcia, J. S., Wei, A. H., ... & Pratz, K. W. (2020). Azacitidine and venetoclax in previously untreated acute myeloid leukemia. *New England journal of medicine*, *383*(7), 617-629.
2. Cherry, E. M., Abbott, D., Amaya, M., McMahon, C., Schwartz, M., Rosser, J., ... & Minhajuddin, M. (2022). Venetoclax and Azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv. 2021; 5 (24): 5565-5573. *Acta Haematol*, *145*, 529-536.